title: Virological failure and subsequent resistance profiles in individuals exposed to atazanavir.
abstract: Few data exist regarding the resistance profile in individuals receiving atazanavir. We found that ritonavir-boosted atazanavir is not associated with the development of primary genotypic resistance in individuals failing this combination, without previous protease inhibitor failure. It is rarely associated with the acquisition of primary mutations in individuals with previous protease inhibitor exposure. This is particularly important because of the increasing use of atazanavir monotherapy, and implies that treatment failure is caused by lack of potency.
authors: Department of HIV Medicine, The Chelsea and Westminster Hospital, Imperial College School of Science, Technology and Medicine, London, UK.
authors: Justin
authors: J
authors: Stebbing
authors: Bif
authors: B
authors: Nathan
authors: Rachael
authors: R
authors: Jones
authors: Alex
authors: A
authors: McKenna
authors: Tom
authors: T
authors: Powles
authors: Mark
authors: M
authors: Bower
authors: Paul
authors: P
authors: Holmes
authors: Brian
authors: B
authors: Gazzard
authors: Mark
authors: M
authors: Nelson
mesh_terms: D000069446:Atazanavir Sulfate; D024921:Drug Resistance, Multiple, Viral; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D009842:Oligopeptides / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D019438:Ritonavir / Q000627:therapeutic use; D017211:Treatment Failure
chemical_list: D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate; D019438:Ritonavir